German biotechnology company Miltenyi Biotec has received the US Food and Drug Administration's(FDA)approval for its CliniMACS CD34 reagent system to prevent graft-versus-host disease(GVHD)in the treatment of acute myeloid leukemia(AML). ...
Tags: Miltenyi Biotec, Blood, Medicine